Skip to content
Delinia logo — Pioneering breakthrough treatments for autoimmune and inflam...

Delinia

Pioneering breakthrough treatments for autoimmune and inflammatory diseases with a focus on enhancing regulatory T cells to maintain immune system balance.

Founded 2015 United States San Francisco, United States 3 employees Acquired Total: $335.00M Biotechnology, Health and Wellness

General Information

Company Name Delinia
Founded Year 2015
Location United States San Francisco, United States
Employees 3
Industries Biotechnology, Health and Wellness
Funding Stage Acquired
Social

BounceWatch is an independent company data service, not affiliated with Delinia. To contact Delinia, visit deliniabio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Delinia compare?

A PDF of Delinia and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Delinia soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Delinia

Delinia is a biotechnology company at the forefront of developing innovative treatments for autoimmune and inflammatory diseases. Founded in 2015 and headquartered in the United States, the company focuses on enhancing Regulatory T Cells (Tregs) to maintain immune system balance. These powerful immune cells are essential for self-tolerance and play a significant role in the pathophysiology of cancer and autoimmune diseases.

The company recently gained attention with a substantial $35.00M Series A investment on 14 September 2016, with notable support from Atlas Venture and Sofinnova Partners. Delinia's lead program aims to potentiate and expand Tregs, positioning itself firmly within the Biotechnology and Health and Wellness sectors. With its commitment to pioneering breakthrough treatments, Delinia stands out as a promising player in the quest to combat autoimmune diseases.

Business keywords: Autoimmune Disease Treatment, Inflammatory Disease Therapies, Regulatory T Cells, Tregs Expansion, Immune System Homeostasis, Novel Therapeutics, Self-tolerance Maintenance, Immune System Balance, Molecule Development, Autoimmune Pathophysiology, Therapeutic Innovation, Clinical Advancements, Immune Regulatory Cells, Scientific Discovery

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Acquisition $300.00M 1
Celgene
01 Jan 2017
Series A $35.00M 2
Atlas Venture, Sofinnova Partners
01 Sep 2016

Delinia Alternatives & Competitors

View All Alternatives
Delinia vs

Rebalancing Immune Function for Chronic Inflammatory and Autoimmune Diseases

Series A
24 employees
Biotechnology, Health Care
Delinia vs
Georgiamune Inc.
Georgiamune Inc. United States

Georgiamune is reprogramming immune signaling pathways to redirect the immune system to fight diseas...

Series A
30 employees
Biotechnology, Health Care
Delinia vs
Q32 Bio Inc.
Q32 Bio Inc. United States

Revolutionizing the future of targeted immune therapeutics

28 employees
Biotechnology, Health Care

FAQ About Delinia

Pioneering breakthrough treatments for autoimmune and inflammatory diseases with a focus on enhancing regulatory T cells to maintain immune system balance.
Delinia was founded in 2015.
Delinia is headquartered in San Francisco, United States.
Delinia operates in Biotechnology and Health and Wellness. Its work centres on Autoimmune Disease Treatment, Inflammatory Disease Therapies, Regulatory T Cells and Tregs Expansion.
Delinia has approximately 3 employees.
Delinia has completed 2 funding rounds, raising a total of $335.00M. The latest funding stage is Acquired.
Top alternatives and competitors to Delinia include Nuvig Therapeutics Inc., Georgiamune Inc., Q32 Bio Inc., Egle Therapeutics, AnaptysBio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Delinia and Nuvig Therapeutics Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Delinia, https://www.bouncewatch.com/company/delinia, updated 30 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout